Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Cherubism Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Cherubism Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Cherubism indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
PASH syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
PASH syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 PASH syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
TNF receptor-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
TNF receptor-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 TNF receptor-associated periodic syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Read →
PAPA syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
PAPA syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 PAPA syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Mevalonate kinase deficiency Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Mevalonate kinase deficiency Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Mevalonate kinase deficiency indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market…
Read →
Deficiency of interleukin-1 receptor antagonist Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Deficiency of interleukin-1 receptor antagonist Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Deficiency of interleukin-1 receptor antagonist indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need,…
Read →
Cryopyrin-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Cryopyrin-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Cryopyrin-associated periodic syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Read →
TAFRO syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
Latest Hotspot
8 min read
TAFRO syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
30 July 2026
2026 TAFRO syndrome indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Juvenile xanthogranuloma Indication Strategy Report 2026: MAPK, Trials and Deals
Latest Hotspot
8 min read
Juvenile xanthogranuloma Indication Strategy Report 2026: MAPK, Trials and Deals
30 July 2026
2026 Juvenile xanthogranuloma indication strategy covering epidemiology, MAPK biology, active trials, transactions, unmet need, competition and market…
Read →
Multicentric reticulohistiocytosis Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Multicentric reticulohistiocytosis Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Multicentric reticulohistiocytosis indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market…
Read →
Schnitzler syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
Latest Hotspot
8 min read
Schnitzler syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Schnitzler syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
Transient abnormal myelopoiesis Indication Strategy Report 2026: GATA1, Trials and Deals
Latest Hotspot
8 min read
Transient abnormal myelopoiesis Indication Strategy Report 2026: GATA1, Trials and Deals
30 July 2026
2026 Transient abnormal myelopoiesis indication strategy covering epidemiology, GATA1 biology, active trials, transactions, unmet need, competition and market…
Read →